{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:44:05Z","timestamp":1789713845357,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T00:00:00Z","timestamp":1455062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s40265-016-0550-y","type":"journal-article","created":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T08:04:34Z","timestamp":1455091474000},"page":"509-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Lesinurad: First Global Approval"],"prefix":"10.1007","volume":"76","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,10]]},"reference":[{"key":"550_CR1","doi-asserted-by":"crossref","first-page":"f5648","DOI":"10.1136\/bmj.f5648","volume":"347","author":"E Roddy","year":"2013","unstructured":"Roddy E, Mallen CD, Doherty M. Gout. BMJ. 2013;347:f5648.","journal-title":"BMJ."},{"issue":"9760","key":"550_CR2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(10)60665-4","volume":"377","author":"CM Burns","year":"2011","unstructured":"Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet. 2011;377(9760):165\u201377.","journal-title":"Lancet."},{"key":"550_CR3","unstructured":"AstraZeneca AB. ZURAMPIC\u00ae (lesinurad) tablets, for oral use: US prescribing information. 2015. http:\/\/www.fda.gov\/ . Accessed 5 Jan 2016."},{"key":"550_CR4","author":"M Gliozzi","year":"2015","unstructured":"Gliozzi M, Malara N, Muscoli S, et al. The treatment of hyperuricemia. Int J Cardiol. 2015. doi: 10.1016\/j.ijcard.2015.08.087 .","journal-title":"Int J Cardiol."},{"key":"550_CR5","unstructured":"Ardea Biosciences Inc. Ardea Biosciences announces expiration of HSR waiting period in connection with proposed merger. 2012. http:\/\/www.ardeabio.com\/ . Accessed 11 Jan 2016."},{"key":"550_CR6","unstructured":"US Food and Drug Administration. FDA approves Zurampic to treat high blood uric acid levels associated with gout. 2015. http:\/\/www.fda.gov\/ . Accessed 11 Jan 2016."},{"key":"550_CR7","unstructured":"European Medicines Agency. Zurampic (lesinurad): summary of opinion. 2015. http:\/\/www.ema.europa.eu . Accessed 21 Dec 2015."},{"issue":"Suppl 3","key":"550_CR8","first-page":"320","volume":"68","author":"L Yeh","year":"2009","unstructured":"Yeh L, Shen Z, Kerr B, et al. RDEA594: a potent URAT1 inhibitor without affecting other important renal transporters, OAT1 and OAT3 [abstract no. THU0452]. Ann Rheum Dis. 2009;68(Suppl 3):320.","journal-title":"Ann Rheum Dis."},{"key":"550_CR9","unstructured":"Terkeltaub R, Perez-Ruiz F, Kopicko J, et al. The safety and efficacy of lower serum urate levels: a pooled analysis of gout subjects receiving lesinurad and xanthine oxidase inhibitors [abstract no. 2354]. Arthritis Rheumatol. 2015;67(Suppl 10):2839\u201340."},{"issue":"Suppl 2","key":"550_CR10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/annrheumdis-2015-eular.1188","volume":"74","author":"R Terkeltaub","year":"2015","unstructured":"Terkeltaub R, Perez-Ruiz F, Storgard C, et al. Relationship between sustained lowering of serum urate levels and improvements in gout flares and tophus area: pooled exploratory analysis of gout subjects receiving lesinurad and xanthine oxidase inhibitor combination therapy [abstract no. SAT0313]. Ann Rheum Dis. 2015;74(Suppl 2):771\u20132.","journal-title":"Ann Rheum Dis."},{"key":"550_CR11","doi-asserted-by":"crossref","unstructured":"Yeh LT, Shen Z, Kerr B, et al. No clinically meaningful drug interactions expected between lesinurad, a novel oral uricosuric agent, and drugs most commonly used by gout patients [abstract no. AB1064]. Ann Rheum Dis. 2012;71(Suppl 3):699.","DOI":"10.1136\/annrheumdis-2012-eular.1063"},{"issue":"Suppl 2","key":"550_CR12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/annrheumdis-2015-eular.2090","volume":"74","author":"AK Tausche","year":"2015","unstructured":"Tausche AK, Alten R, Dalbeth N, et al. Lesinurad monotherapy in gout patients intolerant to xanthine oxidase inhibitors (LIGHT): a randomized, double-blind, placebo-controlled, 6-month phase III clinical trial [abstract no. SAT0307]. Ann Rheum Dis. 2015;74(Suppl 2):769.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 2","key":"550_CR13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/annrheumdis-2015-eular.3273","volume":"74","author":"K Saag","year":"2015","unstructured":"Saag K, Fitz-Patrick D, Kopicko J, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: results from a phase III study in gout patients having an inadequate response to standard of care (CLEAR 1) [abstract no. FRI0320]. Ann Rheum Dis. 2015;74(Suppl 2):540.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 2","key":"550_CR14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/annrheumdis-2015-eular.1238","volume":"74","author":"T Bardin","year":"2015","unstructured":"Bardin T, Keenan R, Khanna P, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: results from a phase III study in gout patients having an inadequate response to standard of care (CLEAR 2) [abstract no. FRI0333]. Ann Rheum Dis. 2015;74(Suppl 2):545.","journal-title":"Ann Rheum Dis."},{"key":"550_CR15","unstructured":"Saag KG, Bardin T, So A, et al. Analysis of gout subjects receiving lesinurad and allopurinol combination therapy by baseline renal function [abstract no. 2112]. Arthritis Rheumatol. 2015;67(Suppl 10):2524\u20135."},{"key":"550_CR16","author":"F Perez-Ruiz","year":"2016","unstructured":"Perez-Ruiz F, Sundy JS, Miner JN, et al. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016. doi: 10.1136\/annrheumdis-2015-207919 .","journal-title":"Ann Rheum Dis."},{"key":"550_CR17","doi-asserted-by":"crossref","unstructured":"Perez-Ruiz F, Sundy J, Krishnan E, et al. Efficacy and safety of lesinurad (RDEA594), a novel URAT1 inhibitor, in combination with allopurinol in allopurinol-refractory gout patients: results from a randomized, blinded, placebo-controlled, phase 2b extension study [abstract no. FRI0370]. Ann Rheum Dis. 2012;71(Suppl 3):439.","DOI":"10.1136\/annrheumdis-2012-eular.2827"},{"issue":"Suppl 2","key":"550_CR18","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/annrheumdis-2015-eular.2182","volume":"74","author":"N Dalbeth","year":"2015","unstructured":"Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a novel selective uric acid reabsorption inhibitor, in combination with febuxostat, in patients with tophaceous gout: the CRYSTAL phase III clinical trial [abstract no. SAT0329]. Ann Rheum Dis. 2015;74(Suppl 2):778.","journal-title":"Ann Rheum Dis."},{"key":"550_CR19","unstructured":"Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad and febuxostat combination therapy: analysis of treatment based on patient baseline renal function [abstract no. 2353]. Arthritis Rheumatol. 2015;67(Suppl 10):2837\u20139."},{"key":"550_CR20","unstructured":"Ardea Biosciences Inc. Lesinurad in combination with a xanthine oxidase inhibitor for treatment of hyperuricemia associated with gout: briefing document for the arthritis advisory committee. 2015. http:\/\/www.fda.gov\/ . Accessed 3 Feb 2016."},{"key":"550_CR21","unstructured":"Dalbeth N, Jones G, Terkeltaub R, et al. Efficacy and safety in patients with tophaceous gout receiving lesinurad and febuxostat combination therapy: interim analysis of an extension study [abstract no. 2352]. Arthritis Rheumatoly. 2015;67(Suppl 10):2836\u20137."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0550-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0550-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0550-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T10:27:45Z","timestamp":1748773665000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0550-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["550"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0550-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,10]]}}}